PATHFINDER 2 Results: What the Galleri Multi-Cancer Blood Test Actually Found
Dr. Dereck Mush, MD, MBA
Grail
Creates multi-cancer early detection blood tests to identify cancer before symptoms appear.
What they do
Grail develops and commercializes blood-based multi-cancer early detection tests. Health systems, employers, and clinicians purchase the Galleri test to screen individuals for over 50 types of cancer from a single blood draw, helping find malignant signals before clinical symptoms manifest.
The record
- Vertical
- Oncology
- Sub-segment
- Early cancer detection
- Product type
- Diagnostics
- Stage
- Public
- Headquarters
- Menlo Park, United States
- Region
- North America
- Founded
- 2015
- Total funding
- $2B raised
Notable investors: ARCH Venture Partners, Sutter Hill Ventures, Jeff Bezos, Bill Gates.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
Beyond HER2 and TROP2: How AbbVie's c-Met Top1i Antibody-Drug Conjugate Earned Two Breakthrough Designations
Dr. Dereck Mush, MD, MBA
Doctors Read Her Mammogram and Saw Nothing. The AI Saw a Tumor.
Dr. Dereck Mush, MD, MBA